Article Data

  • Views 491
  • Dowloads 123

Original Research

Open Access

Tumor response to concurrent chemoradiotherapy depending on PIK3CA gene mutational status among Azerbaijanian cervical cancer patients

  • J. Aliyev1
  • I. Isayev1
  • K. Akbarov1,*,
  • E. Qulyev1
  • L. Melikova1
  • N. Aliyeva1

1National Centre of Oncology, Baku (Azerbaijan)

DOI: 10.12892/ejgo4736.2019 Vol.40,Issue 3,June 2019 pp.443-446

Published: 10 June 2019

*Corresponding Author(s): K. Akbarov E-mail: akperovkamal@yahoo.com

Abstract

Background: The aim of this research was to study PIK3CA mutation depending tumor response to concurrent chemoradiotherapy among Azerbaijanian cervical cancer patients. Materials and Methods: The authors investigated treatment results of 136 Stage IB-IVA cervical cancer patients. Treatment consisted of external beam radiotherapy, weekly cisplatin, and high-dose rate brachytherapy. PIK3CA gene mutations were detected using PIK3CA mutation analysis kit. The association of genetic alterations with clinicopathological characteristics and treatment response were analyzed. Results: The authors revealed activation of PIK3CA gene in 49 (36%) patients in total. PIK3CA mutations were found in five (10.2%) cases of adenocarcinomas and in 44 (89.8%) patients with squamous cell cervical cancer. Of the 136 patients retrieved in this study, 112 (82,3%) patients had complete response, 23 (18,7%) had partial response, and only one had progression of the disease. The frequency of compete response was significantly lower in PIK3CA mutation positive patients (77.6% vs. 92%, p = 0,035). Conclusion: The authors revealed some association between PIK3CA gene alterations and tumor response after chemoradiotherapy in patients with locally advanced cervical cancer. More than one-third of cervical cancer patients are PIK3CA gene mutations carriers and in the future potentially could benefit from newly discovered therapeutic agents which directly target PIK3CA.

Keywords

Cervical carcinoma; Tumor response; PIK3CA gene; Chemoradiotherapy.

Cite and Share

J. Aliyev,I. Isayev,K. Akbarov,E. Qulyev,L. Melikova,N. Aliyeva. Tumor response to concurrent chemoradiotherapy depending on PIK3CA gene mutational status among Azerbaijanian cervical cancer patients. European Journal of Gynaecological Oncology. 2019. 40(3);443-446.

References

[1] “GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012”. Available at: http://globocan.iarc.fr

[2] “Comprehensive cervical cancer control. A guide to essential practice. Second edition”. World Health Organization, 2014, 408.

[3] Vicus D., Sutradhar R., Lu Y., Elit L., Kupets R., Paszat L.: “The association between cervical cancer screening and mortality from cervical cancer: A population based case–control study”. Gynecol. Oncol., 2014, 133, 167.

[4] Aliyev J.A., Isayev I.H., Akbarov K.S., Guliyev E.H.: “Three year relapse free survival of IIA – IIIB stage cervical cancer patients treated by interstitial brachytherapy”. Vopr. Onkol., 2017, 63, 622.

[5] Aliyev J.A., Isayev I.H., Akbarov K.S., Guliyev E.H., Aliyeva N.R., Aliyeva N.S.: “Radiotherapy for cervical cancer by use of polyradiosensitization with cisplatin and gemcitabine - trial results of Azerbaijan National Center of Oncology”. Kaz. Med. J., 2017, 98, 884.

[6] Petrelli F., Stefani A., Raspagliesi F., Lorusso D., Barni S.: “Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis”. Gynecol. Oncol., 2014, 134, 166.

[7] Lesnock J., Farris C., Beriwal S., Krivak T.: “Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy: A cost-effectiveness analysis”. Gynecol. Oncol., 2013, 129, 574.

[8] Minig L., Patrono M., Romero N., Moreno J., Garcia-Donas J.: “Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB”. World J. Clin. Oncol., 2014, 5, 86.

[9] Hanna T., Delaney G., Barton M.: “The population benefit of radiotherapy for gynaecological cancer: Local control and survival estimates”. Radiother. Oncol., 2016, 120, 370.

[10] Ribeiro I., Janssen H., De Brabandere M., Nulens A., De Bal D., Vergote I., Van Limbergen E.: “Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients”. Radiother. Oncol., 2016, 120, 447.

[11] Haque W., Verma V., Fakhreddine M., Hatch S., Butler B., The B.: “Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base”. Gynecol. Oncol., 2017, 144, 28.

[12] Rijkmans E., Nout R., Rutten I., Ketelaars M., Neelis K., Laman M. et al.: “Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy”. Gynecol. Oncol., 2014, 135, 231.

[13] Chong G., Lee Y,. Han H., Lee H., Park J., Hong D., et al.: “Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer”. Gynecol. Oncol., 2018, 148, 97.

[14] Chatzistamatiou K., Moysiadis T., Moschakia V., Panteleris N., AgorastosT.: “Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening”. Gynecol. Oncol., 2016, 142, 120.

[15] Harper D., DeMars L.: “HPV vaccines – A review of the first decade”. Gynecol. Oncol., 2017, 146, 196.

[16] Spaans V., Mahendra I., Purwoto G., Trietsch M., Osse M., Haar N. et al.: “The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway”. Gynecol. Oncol., 2018, 148, 189.

[17] Bregar A., Growdon W.: “Emerging strategies for targeting PI3K in gynecologic cancer”. Gynecol. Oncol., 2016, 140, 333.

[18] Wright A., Howitt B., Myers A., Dahlberg S., Palescandolo E., Van Hummelen P., et al.: “Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix”. Cancer, 2013, 119, 3776.

[19] Janku, F., Wheler J., Westin S., Moulder S., Naing A., Tsimberidou A., et al.: “PI3K/AKT/mTOR Inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations”. Journal of clinical oncology, 2012, 30, 777.

[20] Dong L., Meng F., Wu L., Mitchell A., Block J., Zhang B., et al.: “Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells”. Int. J. Oncol., 2017, 51, 1320.

[21] Jastaniyah N., Yoshida K., Tanderup K., Lindegaard J., Sturdza A., Kirisits C., et al.: “A volumetric analysis of GTVD and CTVHR as defined by the GEC ESTRO recommendations in FIGO stage IIB and IIIB cervical cancer patients treated with IGABT in a prospective multicentric trial (EMBRACE)”. Radiother.Oncol., 2016, 120, 404.

[22] Therasse P., Eisenhauer E., Verweij J.: “RECIST revisited: a review of validation studies on tumour assessment”. Eur. J. Cancer, 2006, 42, 1031.

[23] McIntyre J., Wu J., Craighead P., Phan T., Köbel M., Lees-Miller S., et al.: “PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy”. Gynecol. Oncol., 2013, 128, 409.

[24] Schwarz J., Payton J., Rashmi R., Xiang T., Jia Y., Huettner P., et al.: “Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer”. Clin. Cancer Res., 2012, 18, 1464.

[25] Wang J., Chai Y., Wang T., Liu J., Dai P., Liu Z.: “Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy”. Exp. Mol. Pathol., 2015, 98, 407.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top